Purpose This was an open, randomized, multicenter, phase I/II study to investigate the safety
and tolerability of cetuximab in the first-line treatment of recurrent/metastatic squamous cell …

Background The purpose of this study was to assess the efficacy, safety, and
pharmacokinetics of cisplatin‐based chemotherapy plus cetuximab as first‐line treatment in …

Background The use of cetuximab in combination with platinum (P) plus 5-fluorouracil (F)
has previously been demonstrated to be effective in the treatment of metastatic squamous …

Background Cetuximab in combination with platinum and 5-fluorouracil is the standard of
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …

Background Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-
cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus …

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
(SCCHN) have a poor prognosis, particularly those whose disease has progressed on …

Background: Cetuximab and docetaxel have single-agent activity in squamous cell
carcinoma of the head and neck (SCCHN). The efficacy of their combination was evaluated …

5513 Background: The goal of this study was to investigate the safety and efficacy of
cetuximab (Erbitux), an IgG1 monoclonal antibody targeting the EGFR, given in combination …

The addition of cetuximab (CTX) to the combination of cisplatin and 5-fluorouracil increases
the overall survival (OS) in recurrent/metastatic head and neck squamous cell carcinoma …

BACKGROUND. The epidermal growth factor receptor (EGFR) inhibitor cetuximab is active
in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The …